Imre Noth MD

Pulmonology•Charlottesville, VA

Critical Care Medicine, Interstitial Lung Diseases, Pleural Disease

Professor of Medicine

Join to View Full Profile

1221 Hospital DrFl 2Charlottesville, VA 22908
Phone+1 434-924-5219
Fax+1 434-244-7509

Education & Training

University of ChicagoFellowship, Pulmonary Disease and Critical Care Medicine, 1996 - 1999
University of California Davis HealthResidency, Internal Medicine, 1992 - 1995
University of Arizona College of MedicineClass of 1992

Certifications & Licensure

AZ State Medical License 1995 - Present
CA State Medical License 1993 - Present
VA State Medical License 2018 - 2026
IL State Medical License 1996 - 2020
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations Start of enrollment: 2005 Jan 01
Completed
Phase 1
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
RECRUITING
Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis Start of enrollment: 2007 Aug 01
Completed
Phase 3
Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF Start of enrollment: 2009 Oct 01
Completed
Phase 3
AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis Start of enrollment: 2009 Oct 01
Terminated
Phase 3
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2012 Jul 16
Completed
Phase 2
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
RECRUITING
Treatment of IPF With Laparoscopic Anti-Reflux Surgery Start of enrollment: 2013 Dec 01
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

CD103+ dendritic cell-fibroblast crosstalk via TLR9, TDO2, and AHR signaling drives lung fibrogenesis.
Hannah Carter, Rita Medina Costa, Taylor S Adams, Talon M Gilchrist, Claire E Emch
JCI Insight. 2025-02-18
Genome-wide association study of Idiopathic Pulmonary Fibrosis susceptibility using clinically-curated European-ancestry datasets.
Daniel Chin, Tamara Hernandez-Beeftink, Lauren Donoghue, Beatriz Guillen-Uio, Olivia C Leavy
Medrxiv. 2025-02-02
1 citations
Modulator-refractory cystic fibrosis: Defining the scope and challenges of an emerging at-risk population.
Lindsay Somerville, Larry Borish, Imre Noth, Dana Albon
Therapeutic Advances in Respiratory Disease. 2024-11-15

Other

Management of the patient with severe COPD and cardiovascular disease
Noth I, Schmidt GA
http://www.uptodate.com/contents/management-of-the-patient-with-severe-copd-and-cardiovascular-disea
UpToDate, Wolters Kluwer Health - 2013-02-12

Press Mentions

iTHRIV Backs Promising Researchers to Improve Patient CareJune 10th, 2024
Antibiotics Won't Help Fight Lung-Scarring Disease IDF: StudyJune 4th, 2021
Ofev Doubles the Chance of Improving or Stabilizing IPFMay 26th, 2017
Join now to see all

Grant Support

The role of quantitative CT and radiomic biomarkers for precision medicine in pulmonary fibrosisUNIVERSITY OF VIRGINIA2024–2029
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUNIV OF MASSACHUSETTS MED SCH WORCESTER2024–2026
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUNIV OF MASSACHUSETTS MED SCH WORCESTER2024–2026
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUNIV OF MASSACHUSETTS MED SCH WORCESTER2024–2026
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUNIV OF MASSACHUSETTS MED SCH WORCESTER2024–2026
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyWEILL MEDICAL COLL OF CORNELL UNIV2020–2026
Genome-Wide Association And EXON Sequencing Study In IPFNational Heart, Lung, And Blood Institute2009–2010
Combination Therapy In IPFNational Heart, Lung, And Blood Institute2005–2009
FP And Salmeterol In Preventing COPD ExacerbationsNational Center For Research Resources2006–2007